๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hyderabad
Clinical trial register · India

Clinical Trials in Hyderabad, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 335 Mumbai 261 Hyderabad 238 Bangalore 199 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Asian Institute of Gastroenterology, India39 AstraZeneca36 Novartis Pharmaceuticals15 Bristol-Myers Squibb15 Eli Lilly and Company14
Site location
New Delhi335 Mumbai261 Hyderabad238 Bangalore199 Pune189
All 275 locations
Target enrolment
to

Trials with a site in Hyderabad

238 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Bangalore, Thiruvananthapuram, Mumbai, Nagpur, Nashik, Pune, Hyderabad
2021-10-04
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
448
Bangalore, New Delhi, Hyderabad
2021-09-20
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
New Delhi, Hyderabad, Lucknow, Dehradun
2021-07-28
Active, closed
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979Acute Myeloid Leukemia
DrugsSargramostim·Gm-Csf·Ara-C·Decitabine
Sellas Life Sciences Group
Phase 3
127
Kannur, Hyderabad, Ludhiฤna, New Delhi, Patna
2021-02-08
Active, closed
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659Sickle Cell Disease
DrugEtavopivat
Forma Therapeutics, Inc.
Phase 3
450
Mumbai, Hyderabad, Bangalore, Cutack, New Delhi
2021-01-29
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Surat, Bangalore, Mumbai, Nashik, New Delhi, Hyderabad
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Kozhikode, Pune, Vellore, Hyderabad, Secunderabad, Kolkata
2020-12-11
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Ahemdabad, Ahmedabad, Aurangabad, Bangalore, Belagavi, Howrah, Hyderabad, Jaipur
2020-12-02
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Nagpur, Hyderabad, Bangalore, Lucknow, Manipal, Nashik, Pune, Surat
2020-10-15
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
Hyderabad, Kolkata, Mumbai, Nashik, New Delhi, Pune
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Hyderabad, Kolkata, Mumbai, Nashik, Pune
2020-09-30
Recruiting
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770Dravet Syndrome
DrugClemizole HCl
Epygenix
Phase 3
150
Hyderabad, Surat, Belagavi, Bengaluru, Kochi, Pune, Mumbai, Nagpur
2020-09-15
Active, closed
MINIject Global Long-Term Follow-up Study
NCT04524416Open Angle Glaucoma, Ocular Hypertension
iSTAR Medical
Observational
116
Hyderabad
2020-08-05
Active, closed
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
DrugEteplirsen
Sarepta Therapeutics, Inc.
Phase 3
160
Ahmedabad, Bengaluru, Hyderabad, Madurai, New Delhi, Pune, Vellore
2020-07-13
Active, closed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naรฏve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531Active Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
296
Surat, Bangalore, Belagavi, Hubli, Pune, Hyderabad, Lucknow, Kochi
2020-07-01
Active, closed
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945Pulmonary Arterial Hypertension
DrugMacitentan
Actelion
Phase 3
935
Ahmedabad, Bangalore, Chengalpetu, Coimbatore, Durgapur, Hyderabad, Hyderbad, Kolkata
2020-06-30
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (ฮฒ)-Thalassemia
NCT04143724Beta-Thalassemia
DrugLuspatercept
Celgene
Phase 2
99
Hyderabad, Mumbai, Nagpur, Noida, Kolkata, Vellore
2019-11-07
Active, closed
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NCT03983954ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
NeoTX Therapeutics Ltd.
Phase 1
120
Ahmedabad, Jhajjar, New Delhi, Udaipur, Hyderabad
2019-10-10
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Hyderabad, Ahmedabad, Bangalore, Gurgaon, New Delhi
2019-10-03
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 3
254
Bhubaneswar, Hyderabad
2019-07-26
Active, closed
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
NCT03769506Head and Neck Cancer
Rakuten Medical, Inc.
Phase 3
135
Vadodara, Bangalore, Kochi, Chennai, Hyderabad, Kolkata, Mumbai
2019-05-09
Active, closed
PROSpect: Prone and Oscillation Pediatric Clinical Trial
NCT03896763Acute Respiratory Distress Syndrome in Children
University of Pennsylvania
Not applicable
600
Hyderabad
2019-05-01
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsDurvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Bangalore, Hyderabad, Kolkata, Mumbai, New Delhi
2019-04-29
Active, closed
Intra-operative Pancreatoscopy in Patients With IPMN
NCT03729453Intraductal Papillary Mucinous Neoplasm
Boston Scientific Corporation
Observational
100
Hyderabad
2019-03-20
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab
Novartis Pharmaceuticals
Phase 3
1,882
Mangalore, Kochi, Mumbai, Pune, New Delhi, Chandigarh, Hyderabad, Howrah
2018-12-28
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
DrugsDurvalumab·Bevacizumab
AstraZeneca
Phase 3
724
Bangalore, Bengaluru, Hyderabad, Kolkata, Madurai, Mumbai, Nashik, Pune
2018-11-30
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Ahmedabad, Bangalore, Hyderabad, Jaipur, Ludhiana, Nagpur, Noida, Pune
2018-07-18
Active, closed
International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer
NCT03386734Cervical Cancer
Centre Hospitalier Universitaire de Besancon
Not applicable
989
Hyderabad, Kolkata
2018-05-03
Active, closed
Efficacy Of Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis: A Randomized Controlled Trial
NCT02473341Alcoholic Hepatitis
Dayanand Medical College and Hospital
Phase 3
174
Ludhiana, Chandigarh, Hyderabad, Jaipur, New Delhi
2017-11-14
Recruiting
UNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures
NCT04929821Biliary Obstruction, Bile Duct Stricture, Bile Duct Diseases
QualiMed Innovative Medizinprodukte GmbH
Not applicable
100
Hyderabad
2017-10-16
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Bangalore, Bhubneshwar, Chennai, Hubli, Hyderabad, Karmsad, Mumbai, Nashik
2017-10-11
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Hyderabad, Ahmedabad, Vadodara, Gurgaon, Bangalore, Trivandrum, Mumbai, Nashik
2017-07-12
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Guwahati, Chandigarh, Surat, Gurgaon, Pune, Jaipur, Madurai, Hyderabad
2017-06-26
By invitation
A Clinical Registry of Orthobiologics Procedures
NCT03011398Orthopedic Disorder
Regenexx, LLC
Observational
50,000
Hyderabad
2016-02
Active, closed
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT03127631Prostate Cancer, Cardiovascular Disease
McMaster University
Not applicable
5,000
Sฤซtฤpura, Bengaluru, Bangalore, Hyderabad
2015-10-21
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Jaipur, Hyderabad, Bangalore, Bengaluru, Chennai, Gurgaon, Kochi, New Delhi
2012-01
Active, closed
Comparison of Fulvestrant (FASLODEXโ„ข) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
DrugFulvestrant
AstraZeneca
Phase 3
736
Ansฤrinagar, Bhopal, Hyderabad, Jaipur, Kolkata, Manipal, Marg Jaipur, Mumbai
2005-02-13
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Medtronic
Observational
20,000
Bangalore, Chennai, Gurgaon, Hyderabad, Jaipur, Kochi, New Delhi
1983-01
Rows per page Showing 201–238 of 238
Previous 1 2 3
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/city/hyderabad?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 238 of those studies with a site in Hyderabad.

How many clinical trials are recruiting in Hyderabad?

138 of the 238 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 10 have not yet opened recruitment, 85 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.